Anti-Ribonuclease 3 Antibody
R1511-19
ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetRNASE3
Overview
- SupplierHUABIO
- Product NameAnti-Ribonuclease 3 Antibody
- Delivery Days Customer7
- ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- Applications SupplierWB,IHC-P,ELISA
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID6037
- Target nameRNASE3
- Target descriptionribonuclease A family member 3
- Target synonymsECP, RAF1, RNS3, eosinophil cationic protein, RNase 3, cytotoxic ribonuclease, ribonuclease 3, ribonuclease, RNase A family, 3
- HostRabbit
- IsotypeIgG
- Protein IDP12724
- Protein NameEosinophil cationic protein
- Scientific DescriptionEosinophil cationic protein (ECP) also known as ribonuclease 3 is a basic protein located in the eosinophil primary matrix. In humans, the eosinophil cationic protein is encoded by the RNASE3 gene. ECP is released during degranulation of eosinophils. This protein is related to inflammation and asthma because in these cases, there are increased levels of ECP in the body. There are three glycosolated forms of ECP and consequently ECP has a range of molecular weights from 18-22 kDa. Eosinophil cationic protein and the sequence related eosinophil-derived neurotoxin (RNASE2) are both members of the Ribonuclease A superfamily. Both proteins possess neurotoxic, helmintho-toxic, and ribonucleo-lytic activities. Eosinophil cationic protein is localized to the granule matrix of the eosinophil. Eosinophil granulocytes appear in large numbers in inflammation sites and in response to certain parasitic infections. These cytoplasmic granules contain positively charged proteins that characterize the cells. ECP is one of the four highly basic proteins that enter the surrounding tissues when activated eosinophils degranulate. There are several mechanisms that can be combined to generate an asthma attack, including specific IgE antibodies, activated inflammatory cells, neurogenic mechanisms, hyperresponsiveness and individual hormonal imbalances. Allergic reactions in the lung typically have two phases. The late phase typically occurs several hours after exposure, upon which eosinophils accumulate in the bronchus and release granule proteins that cause bronchial irritability.
- ReactivityHuman
- Reactivity SupplierHuman
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC41116161